Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00751738
Other study ID # 2001060
Secondary ID
Status Completed
Phase Phase 3
First received September 11, 2008
Last updated January 31, 2017
Start date October 2002
Est. completion date October 2005

Study information

Verified date January 2017
Source Forest Laboratories
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098.


Recruitment information / eligibility

Status Completed
Enrollment 330
Est. completion date October 2005
Est. primary completion date October 2005
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients who completed at least 12 months on study 2000098 before inclusion in this study

Exclusion Criteria:

- breast feeding or plan to become pregnant

- used ticlopidine

- were taking Class I or other Class III drugs

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
azimilide dihydrochloride
oral, once daily until sponsor stopped the study

Locations

Country Name City State
Belgium Research Facility Brugge
Belgium Research Facility Mont Godinne
Canada Research Site Halifax Nova Scotia
Canada Research Facility Hamilton Ontario
Canada Research Facility Montreal Quebec
Canada Research Facility Ottawa Ontario
Canada Research Facility Quebec
Canada Research Facility St. Johns Newfoundland and Labrador
Canada Research Facility Toronto Ontario
Canada Research Facility Victoria British Columbia
France Research Facility Lille Cedex
France Research Facility Nantes Cedex
France Research Facility Paris Cedex
France Research Facility Pessac Cedex
France Research Facility Tours Cedex
Germany Research Facility Bad Bevensen
Germany Research Facility Berlin
Germany Research Facility Brandenburg an der Havel
Germany Research Facility Coburg
Germany Research Facility Frankfurt
Germany Research Facility Freiburg
Germany Research Facility Hamburg
Germany Research Facility Heidelberg
Germany Research Facility Ludwigshafen
Germany Research Facility Magdeburg
Germany Research Facility Mannheim
Germany Research Facility Tubingen
Poland Research Facility Gdansk
Poland Research Facility Katowice
Poland Research Facility Lublin
Poland Research Facility Szczecin
Poland Research Facility Warszawa
Spain Research Facility Barcelona
Spain Research Facility Madrid
Spain Research Facility Malaga
Spain Research Facility Valencia
United States Research Facility Baltimore Maryland
United States Research Facility Baltimore Maryland
United States Research Facility Boston Massachusetts
United States Research Facility Bridgeport Connecticut
United States Research Facility Brooklyn New York
United States Research Facility Burlington Massachusetts
United States Research Facility Charleston South Carolina
United States Research Facility Charlottesville Virginia
United States Research Facility Cincinnati Ohio
United States Research Facility Colorado Springs Colorado
United States Research Site Columbia South Carolina
United States Research Facility Dallas Texas
United States Research Facility Dallas Texas
United States Research Site Durham North Carolina
United States Research Facility Erie Pennsylvania
United States Research Facility Fairfax Virginia
United States Research Facility Ft. Lauderdale Florida
United States Research Facility Ft. Myers Florida
United States Research Facility Germantown Tennessee
United States Research Facility Green Bay Wisconsin
United States Research Facility Hershey Pennsylvania
United States Research Facility Houston Texas
United States Research Facility Jacksonville Florida
United States Research Facility Johnson City New York
United States Research Facility Kansas City Kansas
United States Research Facility LaJolla California
United States Research Facility Lancaster Pennsylvania
United States Research Facility Little Rock Arkansas
United States Research Facility Loma Linda California
United States Research Facility Maywood Illinois
United States Research Facility Milwaukee Wisconsin
United States Research Facility Mobile Alabama
United States Research Facility Nashville Tennessee
United States Research Facility New York New York
United States Research Facility New York New York
United States Research Facility Philadelphia Pennsylvania
United States Research Facility Portland Maine
United States Research Facility Rochester New York
United States Research Facility Rochester New York
United States Research Facility Sacramento California
United States Research Facility Salt Lake City Utah
United States Research Facility Spokane Washington
United States Research Facility Toledo Ohio
United States Research Facility Tulsa Oklahoma
United States Research Facility Warren New Jersey
United States Research Facility Washington District of Columbia
United States Research Facility West Orange New York
United States Research Facility Williamsville New York
United States Research Facility Winston-Salem North Carolina
United States Research Facility Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Forest Laboratories

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  France,  Germany,  Poland,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary safety of azimilide in this patient population 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03289429 - Antiarrhythmic and Cardioprotective Effects of Atorvastatin Versus Magnesium Sulfate in Cardiac Valve Replacement Surgery Phase 4
Unknown status NCT01834872 - Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation Phase 4
Withdrawn NCT01026961 - Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers Phase 1/Phase 2
Not yet recruiting NCT05994755 - Association Between Cardiac ARRHYTHMIAs and Glycemic Variability in Patient With Type 2 Diabetes Monitored Through FREEstyle Libre and Bluetooth Technology.
Not yet recruiting NCT06039176 - Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
Withdrawn NCT02575534 - Acute Mechanical Response to Anti-arrhythmic Drug Therapy N/A
Completed NCT02598258 - Hemodynamic Effects of Dry Sauna Followed by Cold Water Immersion in Healthy Subjects N/A
Withdrawn NCT00580255 - Comparison Study of BNP and Thoracic Impedance Measurements on Arrhythmias N/A
Completed NCT02629445 - HIPACE High Frequency Low Energy Pacing to Terminate Fast Ventricular Arrythmias N/A
Recruiting NCT04563091 - Potassium Kinetic During and After Hemodialysis and Potassium Profiling to Prevent Arrhythmias N/A
Completed NCT00589849 - T-Wave Alternans in Acute Myocardial Infarction: An Evaluation of the Time of Testing on Its Prognostic Accuracy N/A
Active, not recruiting NCT03121183 - Medico-economic Evaluation of Strategies for the Lead Extraction of Implantable Defibrillator and Pacemakers N/A
Completed NCT02110004 - Picasso NAV High-Density Mapping Catheter for Signal Analysis of Complex Arrhythmias - First-In-Man Phase 1
Completed NCT02045043 - Genetic Risk Assessment of Defibrillator Events N/A
Recruiting NCT01717469 - Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias Phase 4
Completed NCT00919568 - Monitoring Arrhythmia Patients (IMPACT) N/A
Terminated NCT00124891 - Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia Phase 2
Withdrawn NCT01651702 - Comparison of Carto Versus Ensite 3D Electroanatomical Mapping Systems for Arrhythmias Ablations N/A
Completed NCT02565069 - Identification for the Treatment of Complex Arrhythmias Phase 4
Completed NCT03110146 - EnSite Precision 2.1 Feasibility Study